skip to Main Content
TimeslotTopicSpeaker 
Chair: Tamar Nijsten / TBA
17.00 - 18.00Registration/ Snack
18.00 - 18.10Welcome to CtS
18.10 - 18.50Factors affecting response to immunotherapyTBA
18.50 - 19.25Antigen specific immunotherapiesTBA
19.25 20.00How to deal with increasing drug related costsTBA
20.00Diner
TimeslotTopicSpeaker 
Chair: Alexander van Akkooi / TBA
9.00 - 9.20Controverses in melanoma pathologyAntien MooyaartErasmus MC
9.20 - 9.50Update in UV induced carcinogenesis / tumor immunologyTBA
9.50 - 10.20Adjuvant immunotherapy in melanomaCarolien RobertGustave-Roussy
10.20 - 10.40Impact of 8th AJCC on melanoma outcomesMax MaduUMCG
10.40 - 11.00Coffee Break
Chair: Nicole Kelleners Smeets / TBA
11.00 - 11.30New Dutch CSCC guidelineTBA
11.30 - 11.50Micrographic Mohs surgery for CSCCRenate van den BosErasmus MC
11.50 - 12.10Isolated limb perfusion in CSCCTBA
12.10 - 12.30Anti-PD1 treatment in advanced CSCCDirk SchadendorfUniversity Hospital Essen
12.30-14.00Lunch
Chair: Renate van den Bos / TBA
14.00 - 14.20Sentinel node procedure for head and neck skin cancer?TBA
14.20 - 14.50Prognosis of Merkel cell carcinomaTBA
14.50 - 15.10Avelumab for Merkel cell carcinomaHilde JalvingUMCG
15.10 - 15.40Pro Contra debate
Adjuvante TT vs. adjuvante IO voor BRAF+ stadium III melanoom melanoom
TBA
15.40 - 16.10Coffee Break
Chair: Astrid van der Veldt / TBA
16.10 - 16.40Triple therapy in melanoma: more is better?James LarkinRoyal Marsden Hospital
16.40 - 17.00Melanoma treatment in immunocompromised patientsAstrid vd Veldt?Erasmus MC
17.00- 17.20Locoregional therapy vs. systemic therapy for in transit metastasisTBA
17.20 - 17.40Treatment of brain metsTBA
17.40 -18.00Organisation of melanoma care (in The Netherlands)TBA
TimeslotTopicSpeaker 
Chair: Alexander van Akkooi / TBA
8.45 - 9.05Melanoma mortality: the Breslow paradoxLoes HollesteinErasmus MC
9.05 - 9.35What to do with stage II melanoma?Lex EggermontGustave-Roussy
9.35 - 9.55Risk of melanoma in lentigo malignaJudith ZoutendijkErasmus MC
9.55 - 10.15Skin cancer mortality in transplant recipientsTBA
10.15 - 10.45Coffee Break
Chair: Renate van den Bos / TBA
10.45 - 11.05Comparative RCT of topical AK therapies: 1 year results.Maud JansenMUMC
11.05 - 11.25Skin cancer costs in The NetherlandsEline NoelsErasmus MC
11.25 - 11.45Basal cell carcinoma; genetics and clinical implicationsKlara MosterdMUMC
11.45 - 12.10Views & opinions of skin cancer patients and health care providersTBA
12.10 - 12.30Aggressive adnexal tumors of the skinTBA
12.30 - 13.30Lunch
Chair: Nicole Kelleners Smeets / TBA
13.30 - 13.50Prognostic factors of CSCC progression: UK perspective.Tamar NijstenErasmus MC
13.50 - 14.20How to deal with advanced keratinocytic cancers?Alexander StratigosA. Sygros Hospital, Athene
14.20 - 14.40The expansion of Mohs micrographic surgery in The NetherlandsTBA
14.40 - 15.10Tips & tricks of complex reconstruction in head and neck region.TBA
15.10 - 15.15Closure of Cells to Surgery 2019
Back To Top